Clinical immunogenicity and pharmacokinetic assessments of E3112, a recombinant human hepatocyte growth factor.
E3112 shows a half-life of 19.3 hours and minimal immunogenicity, with no anti-drug antibodies detected in the study.
Where it sits
this study against the rest of the kisspeptin (kp-10) corpusSummary and findings
E3112, a recombinant human hepatocyte growth factor, was assessed for immunogenicity and pharmacokinetics in human serum. The study measured serum levels and anti-drug antibodies (ADA) following intravenous administration. No ADA was detected, and E3112 had a half-life of 19.3 hours.
Abstract
<h4>Aims</h4>E3112 is a recombinant human hepatocyte growth factor (HGF) intended for the treatment of acute liver failure. As the presence of anti-drug antibody (ADA) against E3112 could pose a significant risk in clinical settings if it cross-reacts with the body's natural HGF, we have developed assays for E3112 and its ADA in human serum.<h4>Methods</h4>Assays of E3112 and its ADA developed by ligand binding assays were validated in accordance with bioanalytical guidelines and applied to clinical pharmacokinetic (PK) and immunogenicity assessments.<h4>Results</h4>These assays demonstrated the ability to detect E3112 at a concentration as low as 0.156 ng/mL, whereas the sensitivity of ADA was determined to be 42.3 ng/mL. The validation studies, incorporating quality control for the PK assay and positive control of ADA, substantiated the reproducibility of the assays. The ADA and PK assays were applied to the real sample assays supporting a clinical trial of E3112. Following the intravenous administration of E3112, serum E3112 levels declined with a half-life of 19.3 h. No ADA was detected in predose or postdose samples.<h4>Conclusion</h4>These findings collectively indicate that E3112 exhibited a favorable PK profile with minimal immunogenicity within the clinical context.
Background
This paper addresses the immunogenicity and pharmacokinetics of E3112, a recombinant human hepatocyte growth factor. Prior knowledge indicates that anti-drug antibodies can significantly impact therapeutic efficacy and safety. Understanding the immunogenic profile of E3112 is crucial for its potential use in treating acute liver failure.
Methods
The study utilized ligand binding assays to develop and validate methods for measuring E3112 and ADA in human serum. Specific details regarding the population, sample size, and duration of the study are not reported in abstract. The primary outcome measures included the detection of E3112 levels and the presence of ADA.
Results
E3112 was detected at a concentration as low as 0.156 ng/mL, and the sensitivity of ADA was determined to be 42.3 ng/mL. Following intravenous administration, serum levels of E3112 exhibited a half-life of 19.3 hours. No ADA was detected in either predose or postdose samples.
Interpretation
The findings suggest that E3112 has a favorable pharmacokinetic profile with minimal immunogenicity, which is consistent with the need for safe therapeutic agents. However, the absence of ADA detection does not guarantee long-term immunogenic safety. The lack of reported sample size and other potential confounds limits the strength of these conclusions.
Key findings
- E3112 detected at a concentration as low as 0.156 ng/mL.
- Sensitivity of ADA was determined to be 42.3 ng/mL.
- Half-life of E3112 was 19.3 hours.
- No ADA was detected in predose or postdose samples.
Limitations
- Sample size not reported.
- No information on long-term immunogenicity.
- No details on population or duration of study.